{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T06:05:45Z","timestamp":1792044345857,"version":"4.4.0"},"reference-count":134,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T00:00:00Z","timestamp":1300752000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Endocrinol"],"published-print":{"date-parts":[[2011,5]]},"DOI":"10.1038\/nrendo.2011.37","type":"journal-article","created":{"date-parts":[[2011,3,22]],"date-time":"2011-03-22T09:49:05Z","timestamp":1300787345000},"page":"267-278","source":"Crossref","is-referenced-by-count":134,"title":["Medical treatment of prolactinomas"],"prefix":"10.1038","volume":"7","author":[{"given":"Annamaria","family":"Colao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Savastano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,3,22]]},"reference":[{"key":"BFnrendo201137_CR1","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1016\/S0140-6736(98)03356-X","volume":"352","author":"A Colao","year":"1998","unstructured":"Colao, A. & Lombardi, G. Growth-hormone and prolactin excess. Lancet 352, 1455\u20131461 (1998).","journal-title":"Lancet"},{"key":"BFnrendo201137_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s11102-005-5079-0","volume":"8","author":"A Ciccarelli","year":"2005","unstructured":"Ciccarelli, A., Daly, A. F. & Beckers, A. The epidemiology of prolactinomas. Pituitary 8, 3\u20136 (2005).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR3","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1530\/eje.0.1480325","volume":"148","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur. J. Endocrinol. 148, 325\u2013331 (2003).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR4","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1111\/j.1365-2265.1994.tb02557.x","volume":"41","author":"T Mindermann","year":"1994","unstructured":"Mindermann, T. & Wilson, C. B. Age-related and gender-related occurrence of pituitary adenomas. Clin. Endocrinol. (Oxf.) 41, 359\u2013364 (1994).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR5","volume-title":"Pituitary adenomas in childhood","author":"AM Colao","year":"2006","unstructured":"Colao, A. M. Pituitary adenomas in childhood [online] , (2006)."},{"key":"BFnrendo201137_CR6","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1210\/er.2005-9998","volume":"27","author":"MP Gillam","year":"2006","unstructured":"Gillam, M. P., Molitch, M. E., Lombardi, G. & Colao, A. Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485\u2013534 (2006).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201137_CR7","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.beem.2009.05.003","volume":"23","author":"A Colao","year":"2009","unstructured":"Colao, A. Pituitary tumours: the prolactinoma. Best Pract. Res. Clin. Endocrinol. Metab. 23, 575\u2013596 (2009).","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR8","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1046\/j.1365-2265.2000.01137.x","volume":"53","author":"LD George","year":"2000","unstructured":"George, L. D., Nicolau, N., Scanlon, M. F. & Davies, J. S. Recovery of growth hormone secretion following cabergoline treatment of macroprolactinomas. Clin. Endocrinol. (Oxf.) 53, 595\u2013599 (2000).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR9","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1210\/edrv-13-2-220","volume":"13","author":"JS Bevan","year":"1992","unstructured":"Bevan, J. S., Webster, J., Burke, C. W. & Scanlon, M. F. Dopamine agonists and pituitary tumor shrinkage. Endocr. Rev. 13, 220\u2013240 (1992).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201137_CR10","doi-asserted-by":"publisher","first-page":"452","DOI":"10.3109\/07853899809002486","volume":"30","author":"A Colao","year":"1998","unstructured":"Colao, A., Annunziato, L. & Lombardi, G. Treatment of prolactinomas. Ann. Med. 30, 452\u2013459 (1998).","journal-title":"Ann. Med."},{"key":"BFnrendo201137_CR11","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1517\/13543784.11.6.787","volume":"11","author":"A Colao","year":"2002","unstructured":"Colao, A., di Sarno, A., Pivonello, R., di Somma, C. & Lombardi, G. Dopamine receptor agonists for treating prolactinomas. Expert Opin. Investig. Drugs 11, 787\u2013800 (2002).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"BFnrendo201137_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11102-010-0217-8","volume":"13","author":"L Vilar","year":"2010","unstructured":"Vilar, L. et al. Management of prolactinomas in Brazil: an electronic survey. Pituitary 13, 199\u2013206 (2010).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR13","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1056\/NEJM198608283150903","volume":"315","author":"A Klibanski","year":"1986","unstructured":"Klibanski, A. & Greenspan, S. L. Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N. Engl. J. Med. 315, 542\u2013546 (1986).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1159\/000184630","volume":"44","author":"A Colao","year":"1995","unstructured":"Colao, A. et al. Comparison among different dopamine-agonists of new formulation in the clinical management of macroprolactinomas. Horm. Res. 44, 222\u2013228 (1995).","journal-title":"Horm. Res."},{"key":"BFnrendo201137_CR15","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1210\/jcem.83.3.4674","volume":"83","author":"C Di Somma","year":"1998","unstructured":"Di Somma, C. et al. Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J. Clin. Endocrinol. Metab. 83, 807\u2013813 (1998).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR16","doi-asserted-by":"publisher","first-page":"857","DOI":"10.2169\/internalmedicine.40.857","volume":"40","author":"T Sabuncu","year":"2001","unstructured":"Sabuncu, T., Arikan, E., Tasan, E. & Hatemi, H. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. Intern. Med. 40, 857\u2013861 (2001).","journal-title":"Intern. Med."},{"key":"BFnrendo201137_CR17","doi-asserted-by":"publisher","first-page":"5256","DOI":"10.1210\/jcem.86.11.8054","volume":"86","author":"A Di Sarno","year":"2001","unstructured":"Di Sarno, A. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J. Clin. Endocrinol. Metab. 86, 5256\u20135261 (2001).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR18","doi-asserted-by":"publisher","first-page":"3578","DOI":"10.1210\/jcem.87.8.8722","volume":"87","author":"VQ Passos","year":"2002","unstructured":"Passos, V. Q., Souza, J. J., Musolino, N. R. & Bronstein, M. D. Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J. Clin. Endocrinol. Metab. 87, 3578\u20133582 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s11102-005-5111-4","volume":"8","author":"A Chattopadhyay","year":"2005","unstructured":"Chattopadhyay, A., Bhansali, A. & Masoodi, S. R. Long-term efficacy of bromocriptine in macroprolactinomas and giant prolactinomas in men. Pituitary 8, 147\u2013154 (2005).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR20","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1530\/eje.0.1380286","volume":"138","author":"M De Rosa","year":"1998","unstructured":"De Rosa, M. et al. Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. Eur. J. Endocrinol. 138, 286\u2013293 (1998).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR21","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1111\/j.1365-2265.1990.tb00479.x","volume":"33","author":"G Schettini","year":"1990","unstructured":"Schettini, G. et al. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR). Clin. Endocrinol. (Oxf.) 33, 161\u2013169 (1990).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR22","first-page":"275","volume":"75","author":"A Beckers","year":"1992","unstructured":"Beckers, A. et al. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases. J. Clin. Endocrinol. Metab. 75, 275\u2013280 (1992).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR23","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1517\/14656566.1.3.555","volume":"1","author":"A Colao","year":"2000","unstructured":"Colao, A., Lombardi, G. & Annunziato, L. Cabergoline. Expert Opin. Pharmacother. 1, 555\u2013574 (2000).","journal-title":"Expert Opin. Pharmacother."},{"key":"BFnrendo201137_CR24","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"Webster, J. et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904\u2013909 (1994).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR25","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"Verhelst, J. et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518\u20132522 (1999).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2265.2000.01016.x","volume":"53","author":"A Di Sarno","year":"2000","unstructured":"Di Sarno, A. et al. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas. Clin. Endocrinol. (Oxf.) 53, 53\u201360 (2000).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR27","first-page":"2338","volume":"81","author":"BM Biller","year":"1996","unstructured":"Biller, B. M. et al. Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline. J. Clin. Endocrinol. Metab. 81, 2338\u20132343 (1996).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR28","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1210\/jcem.82.11.4368","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao, A. et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J. Clin. Endocrinol. Metab. 82, 3574\u20133579 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR29","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"Colao, A. et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85, 2247\u20132252 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR30","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1385\/ENDO:20:1-2:75","volume":"20","author":"M De Rosa","year":"2003","unstructured":"De Rosa, M. et al. Hyperprolactinemia in men: clinical and biochemical features and response to treatment. Endocrine 20, 75\u201382 (2003).","journal-title":"Endocrine"},{"key":"BFnrendo201137_CR31","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1210\/jc.2003-030979","volume":"89","author":"A Colao","year":"2004","unstructured":"Colao, A. et al. Outcome of cabergoline treatment in men with prolactinoma: effects of a 24-month treatment on prolactin levels, tumor mass, recovery of pituitary function, and semen analysis. J. Clin. Endocrinol. Metab. 89, 1704\u20131711 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR32","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1210\/jc.2003-030852","volume":"89","author":"M De Rosa","year":"2004","unstructured":"De Rosa, M. et al. Six months of treatment with cabergoline restores sexual potency in hyperprolactinemic males: an open longitudinal study monitoring nocturnal penile tumescence. J. Clin. Endocrinol. Metab. 89, 621\u2013625 (2004).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR33","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1210\/jcem.82.3.3822","volume":"82","author":"A Colao","year":"1997","unstructured":"Colao, A. et al. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment. J. Clin. Endocrinol. Metab. 82, 876\u2013883 (1997).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR34","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1111\/j.1365-2265.2006.02493.x","volume":"64","author":"E Delgrange","year":"2006","unstructured":"Delgrange, E., Duprez, T. & Maiter, D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin. Endocrinol. (Oxf.) 64, 456\u2013462 (2006).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR35","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"Ono, M. et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721\u20134727 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR36","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1530\/EJE-09-0012","volume":"160","author":"E Delgrange","year":"2009","unstructured":"Delgrange, E., Daems, T., Verhelst, J., Abs, R. & Maiter, D. Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur. J. Endocrinol. 160, 747\u2013752 (2009).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1530\/eje.1.02075","volume":"154","author":"A Barlier","year":"2006","unstructured":"Barlier, A. & Jaquet, P. Quinagolide\u2014a valuable treatment option for hyperprolactinaemia. Eur. J. Endocrinol. 154, 187\u2013195 (2006).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR38","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1530\/eje.0.1350548","volume":"135","author":"A Colao","year":"1996","unstructured":"Colao, A. et al. Chronic treatment with CV 205\u2013502 restores the gonadal function in hyperprolactinemic males. Eur. J. Endocrinol. 135, 548\u2013552 (1996).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR39","doi-asserted-by":"publisher","first-page":"668","DOI":"10.7326\/0003-4819-112-9-668","volume":"112","author":"ML Vance","year":"1990","unstructured":"Vance, M. L. et al. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205\u2013502. Ann. Intern. Med. 112, 668\u2013673 (1990).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo201137_CR40","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1365-2265.1990.tb00899.x","volume":"32","author":"R Homburg","year":"1990","unstructured":"Homburg, R., West, C., Brownell, J. & Jacobs, H. S. A double-blind study comparing a new non-ergot, long-acting dopamine agonist, CV 205\u2013502, with bromocriptine in women with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 32, 565\u2013571 (1990).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR41","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1007\/BF03343751","volume":"23","author":"DA De Luis","year":"2000","unstructured":"De Luis, D. A. et al. A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. J. Endocrinol. Invest. 23, 428\u2013434 (2000).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo201137_CR42","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/BF03344963","volume":"17","author":"M Giusti","year":"1994","unstructured":"Giusti, M. et al. A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. J. Endocrinol. Invest. 17, 51\u201357 (1994).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo201137_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/mds.22385","volume":"24","author":"F Andersohn","year":"2009","unstructured":"Andersohn, F. & Garbe, E. Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Mov. Disord. 24, 129\u2013133 (2009).","journal-title":"Mov. Disord."},{"key":"BFnrendo201137_CR44","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1210\/jcem.85.1.6329","volume":"85","author":"PU Freda","year":"2000","unstructured":"Freda, P. U. et al. Long-term treatment of prolactin-secreting macroadenomas with pergolide. J. Clin. Endocrinol. Metab. 85, 8\u201313 (2000).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR45","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1023\/A:1012836331506","volume":"3","author":"JJ Orrego","year":"2000","unstructured":"Orrego, J. J., Chandler, W. F. & Barkan, A. L. Pergolide as primary therapy for macroprolactinomas. Pituitary 3, 251\u2013256 (2000).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR46","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1210\/endo-98-3-598","volume":"98","author":"KJ Gr\u00e4f","year":"1976","unstructured":"Gr\u00e4f, K. J., Neumann, F. & Horowski, R. Effect of the ergot derivative lisuride hydrogen maleate on serum prolactin concentrations in female rats. Endocrinology 98, 598\u2013605 (1976).","journal-title":"Endocrinology"},{"key":"BFnrendo201137_CR47","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1210\/jcem-46-2-196","volume":"46","author":"A Liuzzi","year":"1978","unstructured":"Liuzzi, A. et al. Lisuride hydrogen maleate: evidence for a long lasting dopaminergic activity in humans. J. Clin. Endocrinol. Metab. 46, 196\u2013202 (1978).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR48","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1210\/jcem-63-4-1002","volume":"63","author":"D Dallabonzana","year":"1986","unstructured":"Dallabonzana, D. et al. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride. J. Clin. Endocrinol. Metab. 63, 1002\u20131007 (1986).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1056\/NEJMoa062222","volume":"356","author":"R Schade","year":"2007","unstructured":"Schade, R., Andersohn, F., Suissa, S., Haverkamp, W. & Garbe, E. Dopamine agonists and the risk of cardiac-valve regurgitation. N. Engl. J. Med. 356, 29\u201338 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMoa054830","volume":"356","author":"R Zanettini","year":"2007","unstructured":"Zanettini, R. et al. Valve heart disease and the use of dopamine agonists for Parkinson's disease. N. Engl. J. Med. 356, 39\u201346 (2007).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR51","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman, R. B. et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836\u20132841 (2000).","journal-title":"Circulation"},{"key":"BFnrendo201137_CR52","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/S0002-9149(98)01064-9","volume":"83","author":"JP Singh","year":"1999","unstructured":"Singh, J. P. et al. Prevalence and clinical determinants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart Study). Am. J. Cardiol. 83, 897\u2013902 (1999).","journal-title":"Am. J. Cardiol."},{"key":"BFnrendo201137_CR53","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/0002-8703(89)90739-4","volume":"117","author":"CY Choong","year":"1989","unstructured":"Choong, C. Y. et al. Prevalence of valvular regurgitation by Doppler echocardiography in patients with structurally normal hearts by two-dimensional echocardiography. Am. Heart J. 117, 636\u2013642 (1989).","journal-title":"Am. Heart J."},{"key":"BFnrendo201137_CR54","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1530\/EJE-08-0611","volume":"159","author":"M Kars","year":"2008","unstructured":"Kars, M., Pereira, A. M., Bax, J. J. & Romijn, J. A. Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. Eur. J. Endocrinol. 159, 363\u2013367 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR55","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1210\/jc.2007-1403","volume":"93","author":"A Colao","year":"2008","unstructured":"Colao, A. et al. Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline. J. Clin. Endocrinol. Metab. 93, 3777\u20133784 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR56","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1111\/j.1742-1241.2008.01779.x","volume":"62","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi, F. et al. Treatment with low doses of cabergoline is not associated with increased prevalence of cardiac valve regurgitation in patients with hyperprolactinaemia. Int. J. Clin. Pract. 62, 1864\u20131869 (2008).","journal-title":"Int. J. Clin. Pract."},{"key":"BFnrendo201137_CR57","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1007\/BF03345662","volume":"31","author":"F Bogazzi","year":"2008","unstructured":"Bogazzi, F. et al. Cabergoline therapy and the risk of cardiac valve regurgitation in patients with hyperprolactinemia: a meta-analysis from clinical studies. J. Endocrinol. Invest. 31, 1119\u20131123 (2008).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo201137_CR58","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1097\/MED.0b013e32832d9f64","volume":"16","author":"D Cheung","year":"2009","unstructured":"Cheung, D. & Heaney, A. Dopamine agonists and valvular heart disease. Curr. Opin. Endocrinol. Diabetes Obes. 16, 316\u2013320 (2009).","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"BFnrendo201137_CR59","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1210\/jc.2009-2095","volume":"95","author":"E Valassi","year":"2010","unstructured":"Valassi, E., Klibanski, A. & Biller, B. M. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J. Clin. Endocrinol. Metab. 95, 1025\u20131033 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR60","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1002\/mds.22228","volume":"24","author":"LC Tan","year":"2009","unstructured":"Tan, L. C. et al. Bromocriptine use and the risk of valvular heart disease. Mov. Disord. 24, 344\u2013349 (2009).","journal-title":"Mov. Disord."},{"key":"BFnrendo201137_CR61","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00702-008-0179-4","volume":"116","author":"M Steiger","year":"2009","unstructured":"Steiger, M., Jost, W., Grandas, F. & Van Camp, G. Risk of valvular heart disease associated with the use of dopamine agonists in Parkinson's disease: a systematic review. J. Neural Transm. 116, 179\u2013191 (2009).","journal-title":"J. Neural Transm."},{"key":"BFnrendo201137_CR62","doi-asserted-by":"crossref","unstructured":"Zanettini, R. et al. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc. Ther. doi:10.1111\/j.1755-5922.2010.00169.x.","DOI":"10.1111\/j.1755-5922.2010.00169.x"},{"key":"BFnrendo201137_CR63","first-page":"463","volume":"18","author":"VG Rasmussen","year":"2009","unstructured":"Rasmussen, V. G. et al. Heart abnormalities in Parkinson patients after discontinuation or continuation of ergot-derived dopamine agonists: a treatment-blinded echocardiographic study. J. Heart Valve Dis. 18, 463\u2013469 (2009).","journal-title":"J. Heart Valve Dis."},{"key":"BFnrendo201137_CR64","doi-asserted-by":"crossref","unstructured":"Gu, H., Luck, S., Carroll, P. V., Powrie, J. & Chambers, J. Cardiac valve disease and low-dose dopamine agonist therapy: an artefact of reporting bias? Clin. Endocrinol. (Oxf.) doi: 10.1111\/j.1365\u20132265.2010.03973.x.","DOI":"10.1111\/j.1365-2265.2010.03973.x"},{"key":"BFnrendo201137_CR65","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1016\/0002-9343(83)90418-7","volume":"75","author":"DG Johnston","year":"1983","unstructured":"Johnston, D. G. et al. Hyperprolactinemia. Long-term effects of bromocriptine. Am. J. Med. 75, 868\u2013874 (1983).","journal-title":"Am. J. Med."},{"key":"BFnrendo201137_CR66","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1530\/acta.0.1040139","volume":"104","author":"A Z\u00e1rate","year":"1983","unstructured":"Z\u00e1rate, A., Canales, E. S., Cano, C. & Pilonieta, C. J. Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol. (Copenh.) 104, 139\u2013142 (1983).","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BFnrendo201137_CR67","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1210\/jcem-60-4-764","volume":"60","author":"P Moriondo","year":"1985","unstructured":"Moriondo, P., Travaglini, P., Nissim, M., Conti, A. & Faglia, G. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J. Clin. Endocrinol. Metab. 60, 764\u2013772 (1985).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR68","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(84)90480-X","volume":"2","author":"DG Johnston","year":"1984","unstructured":"Johnston, D. G. et al. Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas. Studies with high-definition computerised tomography. Lancet 2, 187\u2013192 (1984).","journal-title":"Lancet"},{"key":"BFnrendo201137_CR69","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0015-0282(16)47593-X","volume":"41","author":"WS Maxson","year":"1984","unstructured":"Maxson, W. S., Dudzinski, M., Handwerger, S. H. & Hammond, C. B. Hyperprolactinemic response after bromocriptine withdrawal in women with prolactin-secreting pituitary tumors. Fertil. Steril. 41, 218\u2013223 (1984).","journal-title":"Fertil. Steril."},{"key":"BFnrendo201137_CR70","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/j.1365-2265.1987.tb01163.x","volume":"27","author":"C Wang","year":"1987","unstructured":"Wang, C. et al. Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin. Endocrinol. (Oxf.) 27, 363\u2013371 (1987).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR71","first-page":"817","volume-title":"Prolactin. Basic and Clinical Correlates","author":"W Winkelmann","year":"1985","unstructured":"Winkelmann, W., Allolio, B., Deuss, U., Heesen, D. & Kaulen, D. in Prolactin. Basic and Clinical Correlates (eds MacLeod, R. M., Thorner, M. O. & Scapagnini, U.) 817\u2013822 (Liviana Press, Padova, 1985)."},{"key":"BFnrendo201137_CR72","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1530\/acta.0.1250170","volume":"125","author":"C Rasmussen","year":"1991","unstructured":"Rasmussen, C., Brownell, J. & Bergh, T. Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205\u2013502. Acta Endocrinol. (Copenh.) 125, 170\u2013176 (1991).","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BFnrendo201137_CR73","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1111\/j.1365-2265.1991.tb00289.x","volume":"34","author":"JW van't Verlaat","year":"1991","unstructured":"van't Verlaat, J. W. & Croughs, R. J. Withdrawal of bromocriptine after long-term therapy for macroprolactinomas; effect on plasma prolactin and tumour size. Clin. Endocrinol. (Oxf.) 34, 175\u2013178 (1991).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR74","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1530\/acta.0.1260489","volume":"126","author":"C Ferrari","year":"1992","unstructured":"Ferrari, C. et al. Cabergoline in the long-term therapy of hyperprolactinemic disorders. Acta Endocrinol. (Copenh.) 126, 489\u2013494 (1992).","journal-title":"Acta Endocrinol. (Copenh.)"},{"key":"BFnrendo201137_CR75","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/BF03348016","volume":"20","author":"M Muratori","year":"1997","unstructured":"Muratori, M. et al. Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients. J. Endocrinol. Invest. 20, 537\u2013546 (1997).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo201137_CR76","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/BF03343573","volume":"22","author":"S Cannav\u00f2","year":"1999","unstructured":"Cannav\u00f2, S. et al. Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J. Endocrinol. Invest. 22, 354\u2013359 (1999).","journal-title":"J. Endocrinol. Invest."},{"key":"BFnrendo201137_CR77","doi-asserted-by":"publisher","first-page":"2023","DOI":"10.1056\/NEJMoa022657","volume":"349","author":"A Colao","year":"2003","unstructured":"Colao, A. et al. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N. Engl. J. Med. 349, 2023\u20132033 (2003).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR78","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1365-2265.2005.02293.x","volume":"63","author":"M Biswas","year":"2005","unstructured":"Biswas, M. et al. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin. Endocrinol. (Oxf.) 63, 26\u201331 (2005).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR79","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1210\/jc.2008-2103","volume":"94","author":"J Kharlip","year":"2009","unstructured":"Kharlip, J., Salvatori, R., Yenokyan, G. & Wand, G. S. Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J. Clin. Endocrinol. Metab. 94, 2428\u20132436 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR80","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1365-2265.2007.02905.x","volume":"67","author":"A Colao","year":"2007","unstructured":"Colao, A. et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin. Endocrinol. (Oxf.) 67, 426\u2013433 (2007).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR81","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1111\/j.1365-2265.2009.03657.x","volume":"72","author":"MS Huda","year":"2010","unstructured":"Huda, M. S., Athauda, N. B., Teh, M. M., Carroll, P. V. & Powrie, J. K. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal. Clin. Endocrinol. (Oxf.) 72, 507\u2013511 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR82","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0028-2243(92)90094-F","volume":"44","author":"PG Crosignani","year":"1992","unstructured":"Crosignani, P. G. et al. Long-term effects of time, medical treatment and pregnancy in 176 hyperprolactinemic women. Eur. J. Obstet. Gynecol. Reprod. Biol. 44, 175\u2013180 (1992).","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"BFnrendo201137_CR83","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1046\/j.1365-2265.2001.01190.x","volume":"54","author":"S Karunakaran","year":"2001","unstructured":"Karunakaran, S., Page, R. C. & Wass, J. A. The effect of the menopause on prolactin levels in patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 54, 295\u2013300 (2001).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR84","doi-asserted-by":"publisher","first-page":"115","DOI":"10.7326\/0003-4819-100-1-115","volume":"100","author":"MC Koppelman","year":"1984","unstructured":"Koppelman, M. C., Jaffe, M. J., Rieth, K. G., Caruso, R. C. & Louriaux, D. L. Hyperprolactinemia, amenorrhea, and galactorrhea. A retrospective assessment of twenty-five cases. Ann. Intern. Med. 100, 115\u2013121 (1984).","journal-title":"Ann. Intern. Med."},{"key":"BFnrendo201137_CR85","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1046\/j.1365-2265.1996.00824.x","volume":"45","author":"WJ Jeffcoate","year":"1996","unstructured":"Jeffcoate, W. J., Pound, N., Sturrock, N. D. & Lambourne, J. Long-term follow-up of patients with hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 45, 299\u2013303 (1996).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR86","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1210\/jcem-68-2-412","volume":"68","author":"J Schlechte","year":"1989","unstructured":"Schlechte, J., Dolan, K., Sherman, B., Chapler, F. & Luciano, A. The natural history of untreated hyperprolactinemia: a prospective analysis. J. Clin. Endocrinol. Metab. 68, 412\u2013418 (1989).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR87","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0015-0282(16)59292-9","volume":"48","author":"DA Sisam","year":"1987","unstructured":"Sisam, D. A., Sheehan, J. P. & Sheeler, L. R. The natural history of untreated microprolactinomas. Fertil. Steril. 48, 67\u201371 (1987).","journal-title":"Fertil. Steril."},{"key":"BFnrendo201137_CR88","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1210\/jc.2009-1238","volume":"95","author":"OM Dekkers","year":"2010","unstructured":"Dekkers, O. M. et al. Recurrence of hyperprolactinemia after withdrawal of dopamine agonists: systematic review and meta-analysis. J. Clin. Endocrinol. Metab. 95, 43\u201351 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR89","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2006","unstructured":"Casanueva, F. F. et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265\u2013273 (2006).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR90","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1210\/jc.2004-2231","volume":"90","author":"GA Kaltsas","year":"2005","unstructured":"Kaltsas, G. A., Nomikos, P., Kontogeorgos, G., Buchfelder, M. & Grossman, A. B. Clinical review: Diagnosis and management of pituitary carcinomas. J. Clin. Endocrinol. Metab. 90, 3089\u20133099 (2005).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR91","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1159\/000318499","volume":"38","author":"A Colao","year":"2010","unstructured":"Colao, A. et al. Pituitary carcinomas. Front. Horm. Res. 38, 94\u2013108 (2010).","journal-title":"Front. Horm. Res."},{"key":"BFnrendo201137_CR92","doi-asserted-by":"publisher","first-page":"336","DOI":"10.3171\/2010.8.JNS10290","volume":"114","author":"G Zada","year":"2011","unstructured":"Zada, G. et al. Atypical pituitary adenomas: incidence, clinical characteristics, and implications. J. Neurosurg. 114, 336\u2013344 (2011).","journal-title":"J. Neurosurg."},{"key":"BFnrendo201137_CR93","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1159\/000318494","volume":"38","author":"P Fainstein Day","year":"2010","unstructured":"Fainstein Day, P. et al. Gender differences in macroprolactinomas: study of clinical features, outcome of patients and ki-67 expression in tumor tissue. Front. Horm. Res. 38, 50\u201358 (2010).","journal-title":"Front. Horm. Res."},{"key":"BFnrendo201137_CR94","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1530\/EJE-06-0646","volume":"156","author":"I Shimon","year":"2007","unstructured":"Shimon, I., Benbassat, C. & Hadani, M. Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur. J. Endocrinol. 156, 225\u2013231 (2007).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR95","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00006123-199601000-00024","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar, K. et al. Proliferative activity and invasiveness among pituitary adenomas and carcinomas: an analysis using the MIB-1 antibody. Neurosurgery 38, 99\u2013106 (1996).","journal-title":"Neurosurgery"},{"key":"BFnrendo201137_CR96","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1227\/00006123-199604000-00027","volume":"38","author":"K Thapar","year":"1996","unstructured":"Thapar, K., Scheithauer, B. W., Kovacs, K., Pernicone, P. J. & Laws, E. R. Jr. p53 expression in pituitary adenomas and carcinomas: correlation with invasiveness and tumor growth fractions. Neurosurgery 38, 765\u2013770 (1996).","journal-title":"Neurosurgery"},{"key":"BFnrendo201137_CR97","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1210\/er.2002-0008","volume":"24","author":"HE Turner","year":"2003","unstructured":"Turner, H. E., Harris, A. L., Melmed, S. & Wass, J. A. Angiogenesis in endocrine tumors. Endocr. Rev. 24, 600\u2013632 (2003).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201137_CR98","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1023\/A:1026225625897","volume":"6","author":"ME Molitch","year":"2003","unstructured":"Molitch, M. E. Dopamine resistance of prolactinomas. Pituitary 6, 19\u201327 (2003).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR99","first-page":"250","volume":"49","author":"E Delgrange","year":"1998","unstructured":"Delgrange, E., Crabb\u00e9, J. & Donckier, J. Late development of resistance to bromocriptine in a patient with macroprolactinoma. Horm. Res. 49, 250\u2013253 (1998).","journal-title":"Horm. Res."},{"key":"BFnrendo201137_CR100","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2265.2006.02686.x","volume":"66","author":"D McCall","year":"2007","unstructured":"McCall, D. et al. Unusual late development of dopamine agonist resistance in two women with hyperprolactinaemia associated with transition from micro to macroadenoma. Clin. Endocrinol. (Oxf.) 66, 149\u2013150 (2007).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR101","doi-asserted-by":"crossref","unstructured":"Behan, L. A. et al. Secondary resistance to cabergoline therapy in a macroprolactinoma: a case report and literature review. Pituitary doi: 10.1007\/s11102-009-0168-0.","DOI":"10.1007\/s11102-009-0168-0"},{"key":"BFnrendo201137_CR102","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/jc.2009-1360","volume":"95","author":"AG Lania","year":"2010","unstructured":"Lania, A. G. et al. Evolution of an aggressive prolactinoma into a growth hormone secreting pituitary tumor coincident with GNAS gene mutation. J. Clin. Endocrinol. Metab. 95, 13\u201317 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR103","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1210\/jc.2002-020426","volume":"87","author":"MP Gillam","year":"2002","unstructured":"Gillam, M. P., Middler, S., Freed, D. J. & Molitch, M. E. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J. Clin. Endocrinol. Metab. 87, 4447\u20134451 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR104","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0079-6123(10)82012-6","volume":"182","author":"A Colao","year":"2010","unstructured":"Colao, A., Faggiano, A. & Pivonello, R. Somatostatin analogues: treatment of pituitary and neuroendocrine tumors. Prog. Brain Res. 182, 281\u2013294 (2010).","journal-title":"Prog. Brain Res."},{"key":"BFnrendo201137_CR105","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1172\/JCI119779","volume":"100","author":"I Shimon","year":"1997","unstructured":"Shimon, I. et al. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. J. Clin. Invest. 100, 2386\u20132392 (1997).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo201137_CR106","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1055\/s-2007-1011796","volume":"19","author":"MD Bronstein","year":"1987","unstructured":"Bronstein, M. D. et al. Absence of suppressive effect of somatostatin on prolactin levels in patients with hyperprolactinemia. Horm. Metab. Res. 19, 271\u2013274 (1987).","journal-title":"Horm. Metab. Res."},{"key":"BFnrendo201137_CR107","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1365-2265.1986.tb01683.x","volume":"25","author":"SW Lamberts","year":"1986","unstructured":"Lamberts, S. W. et al. The sensitivity of growth hormone and prolactin secretion to the somatostatin analogue SMS 201\u2013995 in patients with prolactinomas and acromegaly. Clin. Endocrinol. (Oxf.) 25, 201\u2013212 (1986).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR108","first-page":"724","volume":"79","author":"Y Greenman","year":"1994","unstructured":"Greenman, Y. & Melmed, S. Expression of three somatostatin receptor subtypes in pituitary adenomas: evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J. Clin. Endocrinol. Metab. 79, 724\u2013729 (1994).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR109","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1159\/000079048","volume-title":"Molecular Pathology of the Pituitary","author":"LJ Hofland","year":"2004","unstructured":"Hofland, L. J. & Lamberts, S. W. J. in Molecular Pathology of the Pituitary (eds Kontogeorgos, G. & Kovacs, K.) 235\u2013252 (Karger, Basel, 2004)."},{"key":"BFnrendo201137_CR110","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1126\/science.288.5463.154","volume":"288","author":"M Rocheville","year":"2000","unstructured":"Rocheville, M. et al. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 288, 154\u2013157 (2000).","journal-title":"Science"},{"key":"BFnrendo201137_CR111","doi-asserted-by":"publisher","first-page":"5414","DOI":"10.1210\/jc.2003-030302","volume":"88","author":"SG Ren","year":"2003","unstructured":"Ren, S. G. et al. Suppression of rat and human growth hormone and prolactin secretion by a novel somatostatin\/dopaminergic chimeric ligand. J. Clin. Endocrinol. Metab. 88, 5414\u20135421 (2003).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR112","doi-asserted-by":"publisher","first-page":"5545","DOI":"10.1210\/jc.2002-020934","volume":"87","author":"A Saveanu","year":"2002","unstructured":"Saveanu, A. et al. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. J. Clin. Endocrinol. Metab. 87, 5545\u20135552 (2002).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR113","first-page":"233","volume":"396","author":"J Gorski","year":"1997","unstructured":"Gorski, J., Wendell, D., Gregg, D. & Chun, T. Y. Estrogens and the genetic control of tumor growth. Prog. Clin. Biol. Res. 396, 233\u2013243 (1997).","journal-title":"Prog. Clin. Biol. Res."},{"key":"BFnrendo201137_CR114","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1172\/JCI0214264","volume":"109","author":"AP Heaney","year":"2002","unstructured":"Heaney, A. P., Fernando, M. & Melmed, S. Functional role of estrogen in pituitary tumor pathogenesis. J. Clin. Invest. 109, 277\u2013283 (2002).","journal-title":"J. Clin. Invest."},{"key":"BFnrendo201137_CR115","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1159\/000123324","volume":"34","author":"SW Lamberts","year":"1982","unstructured":"Lamberts, S. W., Verleun, T. & Oosterom, R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 34, 339\u2013342 (1982).","journal-title":"Neuroendocrinology"},{"key":"BFnrendo201137_CR116","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/er.2004-0016","volume":"26","author":"V Goffin","year":"2005","unstructured":"Goffin, V., Bernichtein, S., Touraine, P. & Kelly, P. A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr. Rev. 26, 400\u2013422 (2005).","journal-title":"Endocr. Rev."},{"key":"BFnrendo201137_CR117","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1056\/NEJM200011093431901","volume":"343","author":"M Esteller","year":"2000","unstructured":"Esteller, M. et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N. Engl. J. Med. 343, 1350\u20131354 (2000).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR118","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-06-2053","volume":"13","author":"S Ekeblad","year":"2007","unstructured":"Ekeblad, S. et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin. Cancer Res. 13, 2986\u20132991 (2007).","journal-title":"Clin. Cancer Res."},{"key":"BFnrendo201137_CR119","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1210\/jc.2010-0644","volume":"95","author":"G Raverot","year":"2010","unstructured":"Raverot, G. et al. Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J. Clin. Endocrinol. Metab. 95, 4592\u20134599 (2010).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR120","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1111\/j.1365-2265.2008.03487.x","volume":"71","author":"AI McCormack","year":"2009","unstructured":"McCormack, A. I. et al. Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours. Clin. Endocrinol. (Oxf.) 71, 226\u2013233 (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR121","doi-asserted-by":"publisher","first-page":"E773","DOI":"10.1227\/01.NEU.0000339115.12803.4E","volume":"64","author":"S Mohammed","year":"2009","unstructured":"Mohammed, S., Kovacs, K., Mason, W., Smyth, H. & Cusimano, M. D. Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64, E773\u2013E774; discussion E774 2009.","journal-title":"Neurosurgery"},{"key":"BFnrendo201137_CR122","doi-asserted-by":"crossref","unstructured":"Thearle, M. et al. Temozolomide (Temodar\u00ae) and capecitabine (Xeloda\u00ae) treatment of an aggressive corticotroph pituitary tumor. Pituitary doi: 10.1007\/s11102-009-0211-1.","DOI":"10.1007\/s11102-009-0211-1"},{"key":"BFnrendo201137_CR123","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1056\/NEJM199605023341809","volume":"334","author":"JM Wilson","year":"1996","unstructured":"Wilson, J. M. Adenoviruses as gene-delivery vehicles. N. Engl. J. Med. 334, 1185\u20131187 (1996).","journal-title":"N. Engl. J. Med."},{"key":"BFnrendo201137_CR124","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1677\/joe.1.06023","volume":"185","author":"EJ Lee","year":"2005","unstructured":"Lee, E. J. & Jameson, J. L. Gene therapy of pituitary diseases. J. Endocrinol. 185, 353\u2013362 (2005).","journal-title":"J. Endocrinol."},{"key":"BFnrendo201137_CR125","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1006\/mthe.2001.0499","volume":"4","author":"JC Williams","year":"2001","unstructured":"Williams, J. C. et al. Regulated, adenovirus-mediated delivery of tyrosine hydroxylase suppresses growth of estrogen-induced pituitary prolactinomas. Mol. Ther. 4, 593\u2013602 (2001).","journal-title":"Mol. Ther."},{"key":"BFnrendo201137_CR126","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s11102-008-0134-2","volume":"12","author":"S Vallette","year":"2009","unstructured":"Vallette, S. et al. Long-term cabergoline therapy is not associated with valvular heart disease in patients with prolactinomas. Pituitary 12, 153\u2013157 (2009).","journal-title":"Pituitary"},{"key":"BFnrendo201137_CR127","doi-asserted-by":"publisher","first-page":"672","DOI":"10.4158\/EP.14.6.672","volume":"14","author":"JK Devin","year":"2008","unstructured":"Devin, J. K., Lakhani, V. T., Byrd, B. F. 3rd & Blevins, L. S. Jr. Prevalence of valvular heart disease in a cohort of patients taking cabergoline for management of hyperprolactinemia. Endocr. Pract. 14, 672\u2013677 (2008).","journal-title":"Endocr. Pract."},{"key":"BFnrendo201137_CR128","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1530\/EJE-08-0213","volume":"159","author":"P Lancellotti","year":"2008","unstructured":"Lancellotti, P. et al. Cabergoline and the risk of valvular lesions in endocrine disease. Eur. J. Endocrinol. 159, 1\u20135 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR129","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1210\/jc.2007-2658","volume":"93","author":"M Kars","year":"2008","unstructured":"Kars, M. et al. Aortic valve calcification and mild tricuspid regurgitation but no clinical heart disease after 8 years of dopamine agonist therapy for prolactinoma. J. Clin. Endocrinol. Metab. 93, 3348\u20133356 (2008).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"BFnrendo201137_CR130","doi-asserted-by":"publisher","first-page":"R11","DOI":"10.1530\/EJE-08-0365","volume":"159","author":"A Wakil","year":"2008","unstructured":"Wakil, A., Rigby, A. S., Clark, A. L., Kallvikbacka-Bennett, A. & Atkin, S. L. Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. Eur. J. Endocrinol. 159, R11\u2013R14 (2008).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR131","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/j.1365-2265.2008.03458.x","volume":"70","author":"N Herring","year":"2009","unstructured":"Herring, N., Szmigielski, C., Becher, H., Karavitaki, N. & Wass, J. A. Valvular heart disease and the use of cabergoline for the treatment of prolactinoma. Clin. Endocrinol. (Oxf.) 70, 104\u2013108 (2009).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR132","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2265.2009.03608.x","volume":"72","author":"LB Nachtigall","year":"2010","unstructured":"Nachtigall, L. B. et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin. Endocrinol. (Oxf.) 72, 53\u201358 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"BFnrendo201137_CR133","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1530\/EJE-09-0989","volume":"162","author":"M Lafeber","year":"2010","unstructured":"Lafeber, M. et al. Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline. Eur. J. Endocrinol. 162, 667\u2013675 (2010).","journal-title":"Eur. J. Endocrinol."},{"key":"BFnrendo201137_CR134","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1365-2265.2010.03827.x","volume":"73","author":"T Tan","year":"2010","unstructured":"Tan, T. et al. Assessment of cardiac valve dysfunction in patients receiving cabergoline treatment for hyperprolactinaemia. Clin. Endocrinol. (Oxf.) 73, 369\u2013374 (2010).","journal-title":"Clin. Endocrinol. (Oxf.)"}],"container-title":["Nature Reviews Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.37","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrendo.2011.37.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T10:22:52Z","timestamp":1712312572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrendo.2011.37"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3,22]]},"references-count":134,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011,5]]}},"alternative-id":["BFnrendo201137"],"URL":"https:\/\/doi.org\/10.1038\/nrendo.2011.37","relation":{},"ISSN":["1759-5029","1759-5037"],"issn-type":[{"value":"1759-5029","type":"print"},{"value":"1759-5037","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,3,22]]}}}